Skip to main content

Eclampsia clinical trials at University of California Health

5 in progress, 4 open to eligible people

Showing trials for
  • Aspirin for Postpartum Patients With Preeclampsia

    open to eligible females ages 18 years and up

    The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.

    at UC Irvine

  • Natural Versus Programmed Frozen Embryo Transfer (NatPro)

    open to eligible females ages 18-41

    NatPro is a two-arm, parallel-group, multi-center, randomized trial in which women undergoing frozen embryo transfer (FET) will be randomized to receive either a modified natural cycle (corpus luteum present) or a programmed cycle (corpus luteum absent).

    at UCSF

  • Expanded NIPT for Pregnancy Complications

    open to eligible females ages 18-60

    This study evaluates the utility of expanded panel non-invasive prenatal testing (NIPT) in detecting confined placental mosaicism of rare autosomal trisomies among pregnancies with placentally-mediated complications, including fetal growth restriction and severe preeclampsia.

    at UCSF

  • Multi-Omics for Maternal Health After Preeclampsia

    open to eligible females ages 18-50

    To develop strategies to identify postpartum women at risk for adverse cardiovascular outcomes and provide them with preventative therapies.

    at UCSD

  • MIRACLE of LIFE Study

    Sorry, in progress, not accepting new patients

    The goal of this observational study is to develop and validate cell-free RNA-based biomarkers for predicting a variety of adverse pregnancy outcomes in a pregnant person population. The main question it aims to answer are: 1. Can cell-free RNA-based biomarkers predict which pregnant people are at greatest risk of developing adverse pregnancy outcomes (e.g., preterm birth, preeclampsia)? 2. What is the performance of such biomarkers when predicting an adverse pregnancy outcome (e.g., sensitivity, specificity, PPV, NPV, TPR)?

    at UCSD

Our lead scientists for Eclampsia research studies include .

Last updated: